ecrin-mdr-crcClinical2022Colorectal CancerColorectal CancerInterventionalhttps://newmdr.ecrin.org/Study/40399China7ECRIN MDRNot yet recruitingfalsePhase II Multicenter, Randomised, Open-Label Study to Evaluate the Efficacy and Safety of Tislelizumab in combination with Cetuximab and Irinotecan versus Investigator’s Choice in patients with previously treated RAS wild-type advanced colorectal cancerInterventions: Experimental Arm:Tislelizumab and cetuximab and irinotecan;Control Arm:Standard Treatment Primary outcome(s): progression-free survival Study Design: Parallel2022-07-1540399ChiCTR2200061365